** Bristol Myers Squibb BMY.N on Thursday forecast its 2026 revenue and profit to exceed Wall Street expectations, noting that reduced prices for its blood thinner Eliquis are expected to boost overall sales

** Median PT of 30 brokerages covering the stock is $60 - data compiled by LSEG

PIPELINE POWERS THE PLOT

** Citigroup ("neutral," PT: $64) says pipeline progress is expected in 2026, though most catalysts to come in H2; expects investor focus on milvexian (blood thinner) readouts and other drug updates

** Morningstar (fair value: $70) says "BMY is holding its financial performance relatively steady despite continuing erosion of sales for its more mature products, although the biggest headwinds are still coming in 2028"

** Piper Sandler ("overweight," PT: $66) says share performance will hinge on several key upcoming data readouts, which should clarify how much the company can grow revenue and earnings after Eliquis loses patent protection

** Leerink Partners ("outperform," PT: $67) says Eliquis will still face a major cliff once generics hit in 2028, and now also factors in Orencia (autoimmune drug) biosimilar pressure starting in 2027

(Reporting by Kanishka Ajmera in Bengaluru)

((Kanishka.Ajmera@thomsonreuters.com))